Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review

Clinical Therapeutics
Carrie Nemerovski, David J Hutchinson

Abstract

Tolvaptan is an oral nonpeptide selective vasopressin V(2)-receptor antagonist indicated for the treatment of clinically relevant hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or syndrome of inappropriate antidiuretic hormone. The objective of this article was to review the pharmacology, efficacy, and tolerability of tolvaptan in the treatment of hypervolemic or euvolemic hyponatremia, heart failure, and autosomal dominant polycystic kidney disease (ADPKD). Articles were identified using MEDLINE (1966-February 28, 2010) and EMBASE (1947-February 28, 2010). Abstracts and proceedings from the annual meetings (2007-2009) of the American Heart Association, the European Society of Cardiology, and the American Society of Nephrology were searched to identify additional relevant publications. Searches were conducted using the terms tolvaptan, vasopressin antagonist, heart failure, polycystic kidney disease, hyponatremia, drug interaction, pharmacokinetics, and pharmacology. The reference lists of the identified publications were reviewed for additional references. All clinical trials that assessed the use of tolvaptan in the management of hypervolemic/euvolemic hyponatremia or heart failure in humans ...Continue Reading

References

Jun 23, 2000·Journal of the American Society of Nephrology : JASN·Kazushige Hanaoka, William B Guggino
Aug 23, 2002·Journal of the American Society of Nephrology : JASN·Peter Igarashi, Stefan Somlo
Jul 10, 2003·American Heart Journal·Craig R LeeKirkwood F Adams
Aug 23, 2003·Journal of the American College of Cardiology·Michael DomanskiUNKNOWN Studies of Left Ventricular Dysfunction
Mar 3, 2004·Nature Medicine·Vicente E TorresVincent H Gattone
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
Aug 26, 2004·Kidney International·Franck A BelibiJared J Grantham
Feb 25, 2005·Journal of the American Society of Nephrology : JASN·Xiaofang WangVicente E Torres
Apr 26, 2005·The American Journal of Cardiology·Kanu Chatterjee
Sep 29, 2005·American Journal of Physiology. Renal Physiology·Lisa C Costello-BoerrigterJohn C Burnett
Oct 13, 2005·Journal of Cardiovascular Pharmacology·Paul J HauptmanCesare Orlandi
Feb 28, 2006·Journal of Cardiac Failure· Heart Failure Society Of America
Feb 28, 2006·Journal of Cardiac Failure·UNKNOWN Heart Failure Society Of America
Mar 28, 2006·The American Journal of Cardiology·Mihai GheorghiadeUNKNOWN Tolvaptan Investigators
Sep 15, 2006·Cleveland Clinic Journal of Medicine·Joseph G Verbalis
Nov 16, 2006·The New England Journal of Medicine·Robert W SchrierUNKNOWN SALT Investigators
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Marvin A KonstamUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
May 13, 2008·Lancet·Guy DecauxGilbert Vassart
May 12, 2009·Current Opinion in Nephrology and Hypertension·Vishal PatelPeter Igarashi

❮ Previous
Next ❯

Citations

Mar 7, 2013·Pediatric Cardiology·Rebecca B RegenJoshua D Koch
Dec 27, 2011·Acta Crystallographica. Section E, Structure Reports Online·Yan-Shu LiangDeng-Ke Liu
Jun 17, 2011·Nephron. Clinical Practice·Pasquale EspositoAntonio Dal Canton
Aug 21, 2013·Hospital Practice·Kristina R Chacko, Samuel H Sigal
Apr 22, 2014·Expert Opinion on Drug Metabolism & Toxicology·Walid M ChalhoubJames H Lewis
Nov 13, 2014·European Journal of Preventive Cardiology·Katrin BurkhardtChrista Meisinger
May 26, 2012·Journal of the American Society of Nephrology : JASN·Horacio J Adrogué, Nicolaos E Madias
Sep 14, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Joseph F DastaIrving B Cassidy
Oct 27, 2011·Current Opinion in Critical Care·Milap Pokaharel, Clay A Block
May 17, 2021·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Martin KieningerKarl-Michael Schebesch

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.